Extrait

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer

Liens

• e-cancer.fr
• Fiche de l'U.S. National Library of Medicine (NLM), sur ClinicalTrials.gov